Loading
You are here: Home » Health Issues » Ipilimumab Receives FDA Priority Review Designation

Ipilimumab Receives FDA Priority Review Designation

August 19th, 2010 | Health News Category : Health Issues,Pharma

Bristol-Myers Squibb Company (NYSE: BMY) has announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the Biologics License Application (BLA) for ipilimumab for the treatment of adult patients with advanced melanoma who have been previously treated.

Original Source of Ipilimumab Receives FDA Priority Review Designation

Related Health Article

    Related tweets from Twitter:

    IPILIMUMAB CPT CODE (12), ipilimumab j code (9), ipilimumab cpt (6), CPT CODE Ipilimumab (5), ipilimumab j-code (4), ipilimumab jcode (3), C9284 Ipilimumab (3), j code ipilimumab (3), hcpcs code for ipilimumab side effects (2), ipilimumab hcpc j code (2), HCPCS code for ipilimumab (2), ipilimumab fda hcpc (2), cpt ipilimumab (2), ipilimumab hcpc code (2), cpt code for ipilimumab (2), cpt c9284 (2), code c9284 (2), ipilimumab j-code 2011 (1), ipilimumab new CPT code C9284 (1), \j-code\ \ipilimumab\ (1)

    Add this post to your favorites social bookmark

    Bookmark and Share